お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はてんかんの治療市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはてんかんの治療の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のてんかんの治療市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはてんかんの治療のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にてんかんの治療市場を分類しています。本研究に含まれる主な企業は：Abbott Laboratories、Cephalon、Novartis、Pfizer、Johnson & Johnson、GlaxoSmithKline、Sanofi、Sunovion Pharmaceuticals、Bausch Health、Takeda

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Anti-epileptic Drugs
    Dietary Supplements
    Vagal Nerve Stimulation
    Surgical Therapies

用途別の市場セグメント：
    Hospitals
    Neurology Centers
    Home Care Settings
    Ambulatory Surgical Centers

本レポートの詳細内容
世界のてんかんの治療市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、てんかんの治療タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のてんかんの治療収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のてんかんの治療市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、てんかんの治療市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

てんかんの治療のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：てんかんの治療のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：てんかんの治療の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章てんかんの治療企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：てんかんの治療の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：てんかんの治療の主要企業の概要を提供し、製品の説明と仕様、てんかんの治療の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Epilepsy is a chronic neurological disorder that cause recurrent unprovoked seizures, characterized by brief and undetectable episodes of involuntary movement involving either a body part (partial) or the entire body (generalized).

Market Analysis and Insights: Global Epilepsy Therapeutics Market
The global Epilepsy Therapeutics market is projected to grow from US$ 4327.1 million in 2024 to US$ 5227.3 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.2% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Epilepsy Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Epilepsy Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Epilepsy Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Epilepsy Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Epilepsy Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Epilepsy Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Abbott Laboratories, Cephalon, Novartis, Pfizer, Johnson & Johnson, GlaxoSmithKline, Sanofi, Sunovion Pharmaceuticals and Bausch Health, etc.

Market Segmentation
By Company
    Abbott Laboratories
    Cephalon
    Novartis
    Pfizer
    Johnson & Johnson
    GlaxoSmithKline
    Sanofi
    Sunovion Pharmaceuticals
    Bausch Health
    Takeda

Segment by Type
    Anti-epileptic Drugs
    Dietary Supplements
    Vagal Nerve Stimulation
    Surgical Therapies

Segment by Application
    Hospitals
    Neurology Centers
    Home Care Settings
    Ambulatory Surgical Centers

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Epilepsy Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Epilepsy Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Epilepsy Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Epilepsy Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Anti-epileptic Drugs
    Table 3. Key Players of Dietary Supplements
    Table 4. Key Players of Vagal Nerve Stimulation
    Table 5. Key Players of Surgical Therapies
    Table 6. Global Epilepsy Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 7. Global Epilepsy Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Epilepsy Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global Epilepsy Therapeutics Market Share by Region (2019-2024)
    Table 10. Global Epilepsy Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global Epilepsy Therapeutics Market Share by Region (2025-2030)
    Table 12. Epilepsy Therapeutics Market Trends
    Table 13. Epilepsy Therapeutics Market Drivers
    Table 14. Epilepsy Therapeutics Market Challenges
    Table 15. Epilepsy Therapeutics Market Restraints
    Table 16. Global Epilepsy Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global Epilepsy Therapeutics Revenue Share by Players (2019-2024)
    Table 18. Global Top Epilepsy Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Epilepsy Therapeutics as of 2023)
    Table 19. Global Epilepsy Therapeutics Industry Ranking 2022 VS 2023 VS 2024
    Table 20. Global 5 Largest Players Market Share by Epilepsy Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Global Key Players of Epilepsy Therapeutics, Headquarters and Area Served
    Table 22. Global Key Players of Epilepsy Therapeutics, Product and Application
    Table 23. Global Key Players of Epilepsy Therapeutics, Product and Application
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Epilepsy Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global Epilepsy Therapeutics Revenue Market Share by Type (2019-2024)
    Table 27. Global Epilepsy Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global Epilepsy Therapeutics Revenue Market Share by Type (2025-2030)
    Table 29. Global Epilepsy Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global Epilepsy Therapeutics Revenue Share by Application (2019-2024)
    Table 31. Global Epilepsy Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global Epilepsy Therapeutics Revenue Share by Application (2025-2030)
    Table 33. North America Epilepsy Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 34. North America Epilepsy Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 35. North America Epilepsy Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 36. North America Epilepsy Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 37. North America Epilepsy Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. North America Epilepsy Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 39. North America Epilepsy Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Europe Epilepsy Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 41. Europe Epilepsy Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 42. Europe Epilepsy Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 43. Europe Epilepsy Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 44. Europe Epilepsy Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Europe Epilepsy Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Europe Epilepsy Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 47. China Epilepsy Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 48. China Epilepsy Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 49. China Epilepsy Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 50. China Epilepsy Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 51. Asia Epilepsy Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 52. Asia Epilepsy Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 53. Asia Epilepsy Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 54. Asia Epilepsy Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 55. Asia Epilepsy Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 56. Asia Epilepsy Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 57. Asia Epilepsy Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Epilepsy Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 63. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 65. Abbott Laboratories Company Details
    Table 66. Abbott Laboratories Business Overview
    Table 67. Abbott Laboratories Epilepsy Therapeutics Product
    Table 68. Abbott Laboratories Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 69. Abbott Laboratories Recent Developments
    Table 70. Cephalon Company Details
    Table 71. Cephalon Business Overview
    Table 72. Cephalon Epilepsy Therapeutics Product
    Table 73. Cephalon Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 74. Cephalon Recent Developments
    Table 75. Novartis Company Details
    Table 76. Novartis Business Overview
    Table 77. Novartis Epilepsy Therapeutics Product
    Table 78. Novartis Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 79. Novartis Recent Developments
    Table 80. Pfizer Company Details
    Table 81. Pfizer Business Overview
    Table 82. Pfizer Epilepsy Therapeutics Product
    Table 83. Pfizer Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 84. Pfizer Recent Developments
    Table 85. Johnson & Johnson Company Details
    Table 86. Johnson & Johnson Business Overview
    Table 87. Johnson & Johnson Epilepsy Therapeutics Product
    Table 88. Johnson & Johnson Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 89. Johnson & Johnson Recent Developments
    Table 90. GlaxoSmithKline Company Details
    Table 91. GlaxoSmithKline Business Overview
    Table 92. GlaxoSmithKline Epilepsy Therapeutics Product
    Table 93. GlaxoSmithKline Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 94. GlaxoSmithKline Recent Developments
    Table 95. Sanofi Company Details
    Table 96. Sanofi Business Overview
    Table 97. Sanofi Epilepsy Therapeutics Product
    Table 98. Sanofi Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 99. Sanofi Recent Developments
    Table 100. Sunovion Pharmaceuticals Company Details
    Table 101. Sunovion Pharmaceuticals Business Overview
    Table 102. Sunovion Pharmaceuticals Epilepsy Therapeutics Product
    Table 103. Sunovion Pharmaceuticals Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 104. Sunovion Pharmaceuticals Recent Developments
    Table 105. Bausch Health Company Details
    Table 106. Bausch Health Business Overview
    Table 107. Bausch Health Epilepsy Therapeutics Product
    Table 108. Bausch Health Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 109. Bausch Health Recent Developments
    Table 110. Takeda Company Details
    Table 111. Takeda Business Overview
    Table 112. Takeda Epilepsy Therapeutics Product
    Table 113. Takeda Revenue in Epilepsy Therapeutics Business (2019-2024) & (US$ Million)
    Table 114. Takeda Recent Developments
    Table 115. Research Programs/Design for This Report
    Table 116. Key Data Information from Secondary Sources
    Table 117. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Epilepsy Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Epilepsy Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. Anti-epileptic Drugs Features
    Figure 4. Dietary Supplements Features
    Figure 5. Vagal Nerve Stimulation Features
    Figure 6. Surgical Therapies Features
    Figure 7. Global Epilepsy Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Epilepsy Therapeutics Market Share by Application: 2023 VS 2030
    Figure 9. Hospitals Case Studies
    Figure 10. Neurology Centers Case Studies
    Figure 11. Home Care Settings Case Studies
    Figure 12. Ambulatory Surgical Centers Case Studies
    Figure 13. Epilepsy Therapeutics Report Years Considered
    Figure 14. Global Epilepsy Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 15. Global Epilepsy Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Epilepsy Therapeutics Market Share by Region: 2023 VS 2030
    Figure 17. Global Epilepsy Therapeutics Market Share by Players in 2023
    Figure 18. Global Top Epilepsy Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Epilepsy Therapeutics as of 2023)
    Figure 19. The Top 10 and 5 Players Market Share by Epilepsy Therapeutics Revenue in 2023
    Figure 20. North America Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. North America Epilepsy Therapeutics Market Share by Type (2019-2030)
    Figure 22. North America Epilepsy Therapeutics Market Share by Application (2019-2030)
    Figure 23. North America Epilepsy Therapeutics Market Share by Country (2019-2030)
    Figure 24. United States Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Canada Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Europe Epilepsy Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 27. Europe Epilepsy Therapeutics Market Share by Type (2019-2030)
    Figure 28. Europe Epilepsy Therapeutics Market Share by Application (2019-2030)
    Figure 29. Europe Epilepsy Therapeutics Market Share by Country (2019-2030)
    Figure 30. Germany Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. France Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. U.K. Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Italy Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Russia Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Nordic Countries Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. China Epilepsy Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. China Epilepsy Therapeutics Market Share by Type (2019-2030)
    Figure 38. China Epilepsy Therapeutics Market Share by Application (2019-2030)
    Figure 39. Asia Epilepsy Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 40. Asia Epilepsy Therapeutics Market Share by Type (2019-2030)
    Figure 41. Asia Epilepsy Therapeutics Market Share by Application (2019-2030)
    Figure 42. Asia Epilepsy Therapeutics Market Share by Region (2019-2030)
    Figure 43. Japan Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. South Korea Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. China Taiwan Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. India Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Australia Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Share by Type (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Share by Application (2019-2030)
    Figure 52. Middle East, Africa, and Latin America Epilepsy Therapeutics Market Share by Country (2019-2030)
    Figure 53. Brazil Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Mexico Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Turkey Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Saudi Arabia Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Israel Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. GCC Countries Epilepsy Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. Abbott Laboratories Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 60. Cephalon Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 61. Novartis Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 62. Pfizer Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 63. Johnson & Johnson Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 64. GlaxoSmithKline Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 65. Sanofi Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 66. Sunovion Pharmaceuticals Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 67. Bausch Health Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 68. Takeda Revenue Growth Rate in Epilepsy Therapeutics Business (2019-2024)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed